TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29468084

Group type: EXPERIMENTAL
Intervention: High intensity supervision therapy programme over 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate intensity supervision therapy programme over 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief falls assessment and advice (Control)
Number of subjects: 0
Study: 29468173

Group type: EXPERIMENTAL
Intervention: High Desipramine (2-3 mg/kg per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low Desipramine (1-2 mg/kg per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29468455

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crizotinib 200 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crizotinib not exceeding 250 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study: 29469964

Group type: COMPARATOR
Intervention: Simvastatin acid (SVA) exposure in 521CC genotype (n=2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Simvastatin acid (SVA) exposure in 521TC genotype (n=15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simvastatin acid (SVA) exposure in 521TT genotype (n=15)
Number of subjects: 32
Study: 29470191

Group type: EXPERIMENTAL
Intervention: Freshly infused transgenic T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryopreserved transgenic T cells
Number of subjects: 0
Study: 29470286

Group type: EXPERIMENTAL
Intervention: Genome-wide association scan (GWAS)
Number of subjects: 234
Study: 29470582

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 327
Study: 29470934

Group type: EXPERIMENTAL
Intervention: Killed bivalent (O1 and O139) whole-cell oral cholera vaccine (OCV), administered in two doses on day 0 and day 14.
Number of subjects: 336
Study: 29471520

Group type: EXPERIMENTAL
Intervention: Second-hand smoke exposure (SHS)
Number of subjects: 500
Study: 29471580

Group type: EXPERIMENTAL
Intervention: T1DM patients
Number of subjects: 1452

Group type: COMPARATOR
Intervention: General non-T1DM population
Number of subjects: 1452
Study: 29471782

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (servo-controlled whole body cooling before 6 hours of age, followed by gradual rewarming after 72 hours)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 17
Study: 29471826

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI) - modified version, consisting of six meetings with family members, facilitated by two interventionists.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparison group) - details not specified in the abstract.
Number of subjects: 0
Study: 29471849

Group type: EXPERIMENTAL
Intervention: Comprehensive implementation strategy based on the Science to Service Laboratory (SSL) including didactic training, performance feedback, and leadership coaching.
Number of subjects: 1800
Study: 29471876

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg twice a day for 3 days
Number of subjects: 10
Study: 29471930

Group type: EXPERIMENTAL
Intervention: Methadone Maintenance Treatment (MMT)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Compulsory Center-Based Treatment (CCT)
Number of subjects: 592
Study: 29471933

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 2692

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BP-BES)
Number of subjects: 2692

Group type: EXPERIMENTAL
Intervention: Platinum-chromium EES (PtCr-EES)
Number of subjects: 2692

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (Re-ZES)
Number of subjects: 2692

Group type: COMPARATOR
Intervention: PtCr-EES
Number of subjects: 2692
Study: 29471937

Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 181
Study: 29472030

Group type: COMPARATOR
Intervention: Aerobic endurance exercise (AEX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 60
Study: 29472176

Group type: EXPERIMENTAL
Intervention: Online advertisements referring to MyProAna
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Online advertisements referring to other websites
Number of subjects: 10000

Group type: COMPARATOR
Intervention: No advertisements (control group)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control users (not shown ads)
Number of subjects: 10000
Study: 29472236

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy (LSFG)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 31
Study: 29472262

Group type: EXPERIMENTAL
Intervention: Parental stress assessment at baseline, 12 and 24 months
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessments at baseline, 12 and 24 months
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Child health and behaviour assessments at baseline, 12 and 24 months
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Physiological tests of allostatic load and telomere length
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Mediation and moderation analysis of family harmony, parenting style, and neighbourhood conditions
Number of subjects: 254
Study: 29472310

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) plus Bevacizumab (Bev)
Number of subjects: 66
Study: 29472357

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study: 29472362

Group type: EXPERIMENTAL
Intervention: Tadekinig alfa 80 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tadekinig alfa 160 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (both doses)
Number of subjects: 23
Study: 29473059

Group type: EXPERIMENTAL
Intervention: Medicaid expansion (intervention group)
Number of subjects: 990

Group type: COMPARATOR
Intervention: No Medicaid expansion (control group)
Number of subjects: 990
Study: 29473191

Group type: EXPERIMENTAL
Intervention: Physical activity, blood pressure, cardiorespiratory fitness (CRF), muscle strength, body composition, and bone mineral density measurements
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Women with BN
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Women with BED
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Participants with a history of anorexia nervosa (AN)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Overall physical fitness in participants with BN or BED
Number of subjects: 156
Study: 29474102

Group type: EXPERIMENTAL
Intervention: Early palliative care visits addressing coping
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Early palliative care visits addressing treatment decisions
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Early palliative care visits addressing advance care planning
Number of subjects: 171
Study: 29474286

Group type: EXPERIMENTAL
Intervention: Cranberry capsules (implemented in April to September 2016)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No cranberry capsules (April to September 2015)
Number of subjects: 167
Study: 29474293

Group type: EXPERIMENTAL
Intervention: Vaginal reconstructive surgery
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Patients younger than 60 years
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Pain medication use prior to surgery
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: No concomitant midurethral sling
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Operating times greater than 210 minutes
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Preexisting history of depression
Number of subjects: 364
Study: 29474336

Group type: EXPERIMENTAL
Intervention: Endocan concentrations in critically ill hematology patients
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Endocan levels in patients with acute respiratory failure
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Total endocan levels higher than 4.46 ng/mL
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Total endocan levels at admission
Number of subjects: 744

Group type: COMPARATOR
Intervention: Endocan levels in critically ill hematology patients compared to healthy subjects
Number of subjects: 744
Study: 29474345

Group type: EXPERIMENTAL
Intervention: Morphine titrated in the postanaesthesia care unit (PACU) and patient-controlled intravenous analgesia for 24 hours.
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Morphine-related adverse events observed in patients.
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: P-glycoprotein polymorphisms (ex-21; ex-26) analysis.
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms (OPRM1, ABCB1, COMT) analysis.
Number of subjects: 404
Study: 29474450

Group type: EXPERIMENTAL
Intervention: Native heterodimeric IL-15 (hetIL-15) treatment
Number of subjects: 2
Study: 29474565

Group type: EXPERIMENTAL
Intervention: Framingham Risk Score (FRS)
Number of subjects: 3015

Group type: EXPERIMENTAL
Intervention: Statin therapy recommendation
Number of subjects: 3015
Study: 29474588

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (p-PCI)
Number of subjects: 7982

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 7982

Group type: COMPARATOR
Intervention: No reperfusion therapy (Control)
Number of subjects: 7982
Study: 29474621

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold
Number of subjects: 0

Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting metallic stent
Number of subjects: 0
Study: 29474723

Group type: EXPERIMENTAL
Intervention: Healthcare costs after myocardial infarction (MI)
Number of subjects: 97252

Group type: EXPERIMENTAL
Intervention: Healthcare resource use patterns
Number of subjects: 97252

Group type: EXPERIMENTAL
Intervention: Long-term healthcare consumption
Number of subjects: 97252
Study: 29475630

Group type: EXPERIMENTAL
Intervention: Food insufficiency
Number of subjects: 0
Study: 29475723

Group type: EXPERIMENTAL
Intervention: Umbralisib (TGR-1202) administered orally once per day in 28-day cycles, starting dose of 50 mg, escalating to 1200 mg, with 800 mg of micronised formulation selected as the recommended phase 2 dose.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Umbralisib (TGR-1202)
Number of subjects: 90
Study: 29475762

Group type: EXPERIMENTAL
Intervention: rBV A/B vaccine (0.5 mL, 40-microgram intramuscular injection)
Number of subjects: 45
Study: 29476021

Group type: EXPERIMENTAL
Intervention: Rituximab Pre- and Post-BEAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without Rituximab)
Number of subjects: 0
Study: 29476383

Group type: EXPERIMENTAL
Intervention: Linsitinib 150 mg orally twice daily on a 28-day cycle
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Linsitinib
Number of subjects: 17
Study: 29476443

Group type: EXPERIMENTAL
Intervention: Two trabecular micro-bypass stents
Number of subjects: 80
Study: 29476499

Group type: EXPERIMENTAL
Intervention: Elagolix
Number of subjects: 1624
Study: 29476612

Group type: EXPERIMENTAL
Intervention: C-terminal fragment of pre-pro-vasopressin (copeptin) measured at admission and re-measured at 72 hours
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: mid-regional pro-atrial natriuretic peptide (MR-proANP)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: mid-regional pro-adrenomedullin (MR-proADM)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: C-terminal pro-endothelin-1 (CT-proET1)
Number of subjects: 164
Study: 29476660

Group type: EXPERIMENTAL
Intervention: Micra leadless pacemaker implantation and concurrent AVJ ablation
Number of subjects: 21
Study: 29476840

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (off MPH)
Number of subjects: 57
Study: 29476876

Group type: COMPARATOR
Intervention: No specific smoking cessation intervention
Number of subjects: 1081
Study: 29477307

Group type: EXPERIMENTAL
Intervention: trivalent oral poliovirus vaccine (tOPV)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: monovalent OPV 2 (mOPV2)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: tOPV together with a dose of inactivated poliovirus vaccine (IPV)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: monovalent high-potency IPV type 2 with mOPV2
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 265
Study: 29477379

Group type: EXPERIMENTAL
Intervention: Infusion of activated and expanded Natural Killer cells (NKAE) from haploidentical donors
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low doses of IL-2
Number of subjects: 18
Study: 29477412

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 20 mg / Quinidine 10 mg (DM/Q) twice daily for 90 days
Number of subjects: 120
Study: 29477578

Group type: EXPERIMENTAL
Intervention: Daily physical activity (DPA) and energy expenditure (EE) assessed over 48 hours using a wearable armband system
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (IS) measured by euglycaemic insulin clamp
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Beta-cell function (BF) estimated by prolonged-OGTT minimal modeling
Number of subjects: 41
Study: 29477778

Group type: EXPERIMENTAL
Intervention: Carlecortemcel-L (expanded cord blood units with cytokines and tetraethylenepentamine)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Double-unit cord blood transplantation (DUCBT)
Number of subjects: 101
Study: 29477796

Group type: EXPERIMENTAL
Intervention: Intensive programme of radiological investigations (maximal approach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom-driven surveillance (minimal approach)
Number of subjects: 0
Study: 29478020

Group type: EXPERIMENTAL
Intervention: Predialysis CKD patients
Number of subjects: 3000
Study: 29478027

Group type: EXPERIMENTAL
Intervention: AF-specific AF6 questionnaire
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Generic 36-Item Short-Form Health Survey
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Higher AF burden
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison with Swedish age- and sex-matched population
Number of subjects: 54
Study: 29478026

Group type: EXPERIMENTAL
Intervention: Atenolol (β1-adrenergic receptor blocker) - monotherapy
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Atenolol (β1-adrenergic receptor blocker) - add-on therapy
Number of subjects: 699
Study: 29478148

Group type: EXPERIMENTAL
Intervention: Vaginal antetheca submucosal-retropubic space mesh repair surgery
Number of subjects: 316
Study: 29478343

Group type: EXPERIMENTAL
Intervention: Avelumab (human IgG1 monoclonal antibody against PD-L1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29478347

Group type: EXPERIMENTAL
Intervention: One-dose MMR
Number of subjects: 7436
Study: 29478790

Group type: EXPERIMENTAL
Intervention: TST followed by QFT if TST was positive
Number of subjects: 0
Study: 29479457

Group type: EXPERIMENTAL
Intervention: Structured internet-based exercise program (e-training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No e-training intervention (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 0
Study: 29479466

Group type: COMPARATOR
Intervention: Standard behavioural weight loss programme
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard programme plus partner involvement (Enhanced)
Number of subjects: 40
Study: 29479473

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29480210

Group type: EXPERIMENTAL
Intervention: IONIS-HTTRX trial (NCT02519036)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRECISION-HD1 (NCT03225833)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRECISION-HD2 (NCT03225846)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FIRST-HD deutetrabenazine trial (NCT01795859)
Number of subjects: 0
Study: 29480357

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg/week for 24 weeks followed by ETN for 28 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (PBO) for 28 weeks after initial treatment with ETN
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 53
Study: 29480444

Group type: EXPERIMENTAL
Intervention: Exercise behavior and physical fitness assessment shortly after diagnosis
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Previous exercise and walking behavior
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Current exercise behavior
Number of subjects: 227
Study: 29481376

Group type: EXPERIMENTAL
Intervention: H2 powered exoskeleton with electroencephalography-based brain-machine interface
Number of subjects: 5
Study: 29481659

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 53
Study: 29481737

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (weight-tiered: 50 mg for 10 to <25 kg, 87.5 mg for 25 to <50 kg, 125 mg for ≥50 kg) administered weekly for 24 months.
Number of subjects: 0
Study: 29481881

Group type: EXPERIMENTAL
Intervention: Filovirus Animal Non-Clinical Group assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha Diagnostics International assay
Number of subjects: 0
Study: 29481926

Group type: EXPERIMENTAL
Intervention: 5,000 units of unfractionated heparin (UFH)
Number of subjects: 36
Study: 29481970

Group type: EXPERIMENTAL
Intervention: Combination of vedolizumab and adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current therapies (biologic agents)
Number of subjects: 0
Study: 29482538

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study: 29482554

Group type: EXPERIMENTAL
Intervention: Moderate intensity thresholds identified through regression and ROC analyses
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vigorous intensity thresholds identified through regression and ROC analyses
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds for moderate intensity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds for vigorous intensity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of heuristic thresholds
Number of subjects: 120
Study: 29482567

Group type: EXPERIMENTAL
Intervention: Normal pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-eclampsia (PE)
Number of subjects: 0
Study: 29482601

Group type: EXPERIMENTAL
Intervention: High-intensity, low-volume interval training (HIIT-low volume)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous aerobic exercise (CAE)
Number of subjects: 60
Study: 29482616

Group type: EXPERIMENTAL
Intervention: CCQ cutoff of 1.4
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CCQ
Number of subjects: 126
Study: 29483030

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control group (children not enrolled in the NASIMMUNE study)
Number of subjects: 454
Study: 29483101

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg)
Number of subjects: 51
Study: 29483841

Group type: EXPERIMENTAL
Intervention: Peripheral microvascular endothelial dysfunction (ED)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: ACPA negativity
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Higher triglycerides concentrations
Number of subjects: 874
Study: 29483892

Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD) for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline mean monthly number of attacks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: End of 3-month diet mean monthly number of attacks
Number of subjects: 18
Study: 29483909

Group type: COMPARATOR
Intervention: Autoantibodies (AAb) against G protein-coupled receptors (GPCRs) in patients with POAG and OHT.
Number of subjects: 0
Study: 29484099

Group type: EXPERIMENTAL
Intervention: Sunbeds with UVB radiation
Number of subjects: 0
Study: 29484172

Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation (3 l/min oxygen by nasal cannula)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation
Number of subjects: 30
Study: 29484177

Group type: EXPERIMENTAL
Intervention: MUAC insertion tape
Number of subjects: 21

Group type: COMPARATOR
Intervention: Click-MUAC devices
Number of subjects: 21
Study: 29484197

Group type: EXPERIMENTAL
Intervention: 8-week bilingual yoga intervention adapted for arthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-assisted self-interview (CASI) for data collection
Number of subjects: 0
Study: 29484198

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) program consisting of exercises designed to improve balance and gait, conducted over 8 weeks, twice weekly.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving the current standard of care following STN-DBS, which does not include prescription of PT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) program
Number of subjects: 0
Study: 29484495

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 2195

Group type: COMPARATOR
Intervention: Levodopa alone or in combination with a dopamine agonist
Number of subjects: 2195

Group type: COMPARATOR
Intervention: Dopaminergic monotherapy
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Dopamine-substituting therapies
Number of subjects: 2195
Study: 29484580

Group type: EXPERIMENTAL
Intervention: XIENCE V/PROMUS everolimus-eluting stents
Number of subjects: 2010
Study: 29485066

Group type: EXPERIMENTAL
Intervention: Hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiation therapy, 34 Gy in 10 fractions within 2 weeks, followed by a boost of 10 Gy in 5 fractions within 1 week for BCS patients.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment of 35 Gy in 15 fractions within 3 weeks (not explicitly detailed in the abstract).
Number of subjects: 50
Study: 29485355

Group type: EXPERIMENTAL
Intervention: Classical homeopathy for prophylaxis of recurrent urinary tract infections
Number of subjects: 0